Connector hub
Recent articles
Neuroscientist Mac Shine interviews researchers whose work traverses traditional boundaries.
How can we fold cellular-level details into whole-brain neuroimaging networks?
I got answers from Bratislav Misic, who is inventing practical ways to connect the brain’s microscopic features with its macroscopic organization.
How can we fold cellular-level details into whole-brain neuroimaging networks?
I got answers from Bratislav Misic, who is inventing practical ways to connect the brain’s microscopic features with its macroscopic organization.
What happens when a histopathologist teams up with computational modelers?
Answers emerge in my chat with Nicola Palomero-Gallagher, a rare example of someone who connects the brain’s microscopic constituents and macroscopic features.
What happens when a histopathologist teams up with computational modelers?
Answers emerge in my chat with Nicola Palomero-Gallagher, a rare example of someone who connects the brain’s microscopic constituents and macroscopic features.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.